Heidelberg Pharma AG (HPHA.DE)
- Previous Close
3.0200 - Open
3.0900 - Bid 2.9800 x --
- Ask 3.0900 x --
- Day's Range
3.0900 - 3.1000 - 52 Week Range
2.1100 - 3.1100 - Volume
2,479 - Avg. Volume
4,870 - Market Cap (intraday)
144.475M - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4100 - Earnings Date Jul 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.70
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. It also develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.
heidelberg-pharma.comRecent News: HPHA.DE
View MorePerformance Overview: HPHA.DE
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HPHA.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HPHA.DE
View MoreValuation Measures
Market Cap
140.75M
Enterprise Value
104.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.61
Price/Book (mrq)
3.93
Enterprise Value/Revenue
12.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.48%
Return on Equity (ttm)
-59.35%
Revenue (ttm)
6.85M
Net Income Avi to Common (ttm)
-20.83M
Diluted EPS (ttm)
-0.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
20.68M
Total Debt/Equity (mrq)
0.61%
Levered Free Cash Flow (ttm)
-23.55M